Odelniqva (Dapagliflozin)

Dapagliflozin, the active ingredient in Odelniqva, is a sodium‑glucose co‑transporter‑2 (SGLT2) inhibitor presented as a tablet for oral use. It helps improve blood‑sugar control in adults with type 2 diabetes mellitus. GNH USA supplies Odelniqva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Odelniqva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Odelniqva (dapagliflozin) is an SGLT2‑inhibitor used in the management of metabolic disorders that affect glucose handling.

- Type 2 diabetes mellitus: improves glycaemic control when added to diet, exercise and other antidiabetic agents. - Heart failure with reduced ejection fraction: reduces risk of cardiovascular death and hospitalization. - Chronic kidney disease (CKD) in adults: slows progression of renal function decline. - Cardiovascular risk reduction: lowers incidence of major adverse cardiovascular events in high‑risk patients. - Adjunct to lifestyle therapy: assists in weight management as part of a comprehensive diabetes plan.

Odelniqva may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Genital mycotic infection: more frequent in women and uncircumcised men. - Urinary tract infection: symptoms include dysuria and increased frequency. - Increased urination: due to osmotic diuresis. - Thirst or dry mouth: related to fluid loss. - Mild hypotension: especially after initiation or dose escalation. - Elevated LDL‑cholesterol: modest rise observed in lipid panels.

Serious or Rare Side Effects: - Ketoacidosis (euglycaemic): metabolic acidosis with normal or mildly elevated glucose. - Severe dehydration: can lead to acute kidney injury. - Fournier's gangrene: necrotizing fasciitis of the perineum, a medical emergency. - Acute kidney injury: rapid decline in renal function. - Severe hypersensitivity reactions: including angioedema and anaphylaxis. - Bone fracture: rare reports of increased fracture risk.

Before initiating Odelniqva, clinicians should assess patient suitability and monitor for specific safety concerns.

- Renal function: evaluate eGFR; avoid if severely impaired. - Volume status: ensure adequate hydration to reduce hypotension risk. - Electrolytes: monitor serum potassium and sodium periodically. - Cardiovascular status: caution in patients with low blood pressure or on diuretics. - Pregnancy and lactation: avoid use; insufficient safety data. - Concomitant SGLT2 inhibitors: do not combine with other agents of the same class. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Dapagliflozin can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Loop or thiazide diuretics: may exacerbate dehydration and hypotension. - Insulin or insulin secretagogues: increase risk of hypoglycaemia. - Strong CYP3A4 inducers (e.g., rifampicin): reduce dapagliflozin exposure.

Moderate Interactions (Monitor Closely): - ACE inhibitors/ARBs: additive blood‑pressure‑lowering effect. - NSAIDs: may impair renal function when combined. - Anticoagulants: monitor for changes in bleeding risk. - Lipid‑lowering agents: occasional modest rise in LDL‑cholesterol. - Alcohol: enhances diuretic effect and may worsen hypotension.